Systemic sclerosis pulmonary – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:56 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Systemic sclerosis pulmonary – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Tulisokibart in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-tulisokibart-in-patients-with-systemic-sclerosis-associated-with-interstitial-lung-disease/ Thu, 07 May 2026 05:47:11 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-tulisokibart-in-patients-with-systemic-sclerosis-associated-with-interstitial-lung-disease/ This clinical trial is studying Systemic Sclerosis Associated with Interstitial Lung Disease, a condition in which the immune system causes hardening of the skin and can also lead to scarring in the lungs. The treatment being tested is tulisokibart (also called MK-7240/PRA023), given by vein as an infusion. The purpose of the study is to see how safe this medicine is and whether it may help people with this lung disease. Some participants will receive tulisokibart and others will receive placebo.

The study is planned to last about 50 weeks for each person. During the study, treatment is given at regular times, and health checks are done over the course of the trial to watch for side effects and other changes in health. The study also looks at lung function, which means how well the lungs move air in and out.

]]> Study of rituximab and mycophenolate mofetil combination therapy compared to placebo for patients with interstitial lung disease related to systemic sclerosis https://clinicaltrials.eu/trial/study-on-the-effects-of-rituximab-and-mycophenolate-mofetil-in-patients-with-interstitial-lung-disease-from-systemic-sclerosis/ Wed, 29 Apr 2026 14:58:47 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-rituximab-and-mycophenolate-mofetil-in-patients-with-interstitial-lung-disease-from-systemic-sclerosis/ This study focuses on Interstitial Lung Disease related to systemic sclerosis, a condition where lung tissue becomes scarred and breathing becomes difficult. The study will test a combination of two medications: rituximab and mycophenolate mofetil. The purpose is to evaluate how well this combination treatment works on lung function compared to using mycophenolate mofetil with a placebo.

The treatment involves receiving rituximab through intravenous infusions, while mycophenolate mofetil is taken by mouth. Some participants will receive rituximab with mycophenolate mofetil, while others will receive a placebo with mycophenolate mofetil. Sodium chloride solution will be used for the intravenous administration of medications.

The study will last 48 weeks, during which participants’ lung function will be monitored. Throughout the study, various tests will be performed to check breathing capacity and overall health status. The treatment involves taking mycophenolate mofetil daily and receiving rituximab or placebo at specific times during the study period.

]]> Study on Vixarelimab for Patients with Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease https://clinicaltrials.eu/trial/study-on-vixarelimab-for-patients-with-idiopathic-pulmonary-fibrosis-and-systemic-sclerosis-associated-interstitial-lung-disease/ Wed, 29 Apr 2026 14:23:43 +0000 https://clinicaltrials.eu/trial/study-on-vixarelimab-for-patients-with-idiopathic-pulmonary-fibrosis-and-systemic-sclerosis-associated-interstitial-lung-disease/ This clinical trial is focused on studying two lung-related diseases: Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease. The treatment being tested is called Vixarelimab, which is given as a solution for injection. The study will compare the effects of Vixarelimab with a placebo to understand its impact on lung function in patients with these conditions.

The purpose of the study is to evaluate how well Vixarelimab works in improving lung function. Participants will receive either Vixarelimab or a placebo through subcutaneous injection, which means the injection is given under the skin. The study will last for a period of up to 104 weeks, during which various health assessments will be conducted to monitor changes in lung function and overall health.

Throughout the study, participants will undergo regular check-ups to measure changes in their lung capacity and other health indicators. The study aims to provide valuable information on the safety and effectiveness of Vixarelimab in treating these lung diseases, potentially leading to better treatment options in the future.

]]>